Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Xiaoyi Wang, Amer M. Zeidan, Rong Wang, Jan P. Bewersdorf, Chi Zhang, Nikolai A. Podoltsev, Scott F. Huntington, Steven D. Gore & Xiaomei Ma. (2021) Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 62:10, pages 2438-2447.
Read now
Read now
Eytan M. Stein, Gaetano Bonifacio, Dominick Latremouille-Viau, Sherry Shi, Annie Guerin, Eric Q. Wu, Islam Sadek & Xiting Cao. (2021) Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis. Leukemia & Lymphoma 62:6, pages 1411-1421.
Read now
Read now
M. Cruijsen, W.J.F.M van der Velden, A.F.J. de Haan, S. K. Klein, M. Hoogendoorn, Y. Tromp, B. de Valk, B. van Rees, F. de Boer, E. van der Spek, J. Pruijt, L.F. Verdonck, E. Vellenga, N. Blijlevens, A. A. van de Loosdrecht & G. Huls. (2020) Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study. Leukemia & Lymphoma 61:11, pages 2752-2755.
Read now
Read now
Amy J. Davidoff, Xin Hu, Jan Philipp Bewersdorf, Rong Wang, Nikolai A. Podoltsev, Scott F. Huntington, Steven D. Gore, Xiaomei Ma & Amer M. Zeidan. (2020) Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. Leukemia & Lymphoma 61:5, pages 1178-1187.
Read now
Read now
Amer M. Zeidan, Xin Hu, Weiwei Zhu, Maximilian Stahl, Rong Wang, Scott F. Huntington, Smith Giri, Jan Philipp Bewersdorf, Nikolai A. Podoltsev, Steven D. Gore, Xiaomei Ma & Amy J. Davidoff. (2020) Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 61:2, pages 397-408.
Read now
Read now
Amer M. Zeidan, Weiwei Zhu, Maximilian Stahl, Rong Wang, Scott F. Huntington, Smith Giri, Nikolai A. Podoltsev, Steven D. Gore, Xiaomei Ma & Amy J. Davidoff. (2019) RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 60:13, pages 3181-3187.
Read now
Read now
Amer M. Zeidan, Rong Wang, Cary P. Gross, Steven D. Gore, Scott F. Huntington, Thomas Prebet, Gregory A. Abel, Amy J. Davidoff & Xiaomei Ma. (2017) Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leukemia & Lymphoma 58:4, pages 982-985.
Read now
Read now
Articles from other publishers (25)
Shinichi Ogawa, Tatsuhiro Sakamoto, Ryota Matsuoka, Kantaro Ishitsuka, Yasuko Ogino, Ayano Sootome, Kenichi Makishima, Chikashi Yoshida, Yufu Ito, Seiichi Shimizu, Takuya Suyama, Atsushi Shinagawa, Takayoshi Ito, Naoshi Obara, Manabu Kusakabe, Mamiko Sakata‐Yanagimoto, Yasushi Miyazaki, Yasuhito Nannya & Shigeru Chiba. (2023) Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine. Cancer Reports.
Crossref
Crossref
E Dawn Flick, Howard R Terebelo, Susan Fish, Amani Kitali, Vrinda Mahajan, Melissa Nifenecker, Kristen Sullivan, Paul Thaler, Sarah Ussery & David L Grinblatt. (2023) The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research. The Oncologist 28:8, pages 657-663.
Crossref
Crossref
Carmelo Gurnari, Zhuoer Xie & Amer M. Zeidan. (2022) How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms. Clinical Hematology International 5:1, pages 8-20.
Crossref
Crossref
Douglas Tremblay, Ian Baine & John Mascarenhas. (2022) Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide. Clinical Lymphoma Myeloma and Leukemia 22:12, pages e1067-e1074.
Crossref
Crossref
Silvia Park, So Yeon Park, Je‐Hwan Lee, Eun‐Ji Choi, Kyoo‐Hyung Lee, Sung‐Soo Yoon, Junshik Hong, Dong‐Yeop Shin & Yoo‐Jin Kim. (2022) Five‐day versus 7‐day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial. Cancer 128:23, pages 4095-4108.
Crossref
Crossref
Uma M. Borate. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
20
.
Yasushi Miyazaki, Toru Kiguchi, Shinya Sato, Kensuke Usuki, Ken Ishiyama, Yoshikazu Ito, Takahiro Suzuki, Jun Taguchi, Shigeru Chiba, Nobuaki Dobashi, Akihiro Tomita, Hironori Harada, Hiroshi Handa, Shigeo Horiike, Tomoya Maeda, Mitsuhiro Matsuda, Motoshi Ichikawa, Tomoko Hata, Sumihisa Honda, Satoshi Iyama, Hitoshi Suzushima, Yukiyoshi Moriuchi, Toshiro Kurokawa, Kenichi Yokota, Shigeki Ohtake, Takahiro Yamauchi, Itaru Matsumura, Hitoshi Kiyoi, Tomoki Naoe, Yasushi Miyazaki, Kensuke Usuki, Ken Ishiyama, Yoshikazu Ito, Takahiro Suzuki, Jun Taguchi, Shigeru Chiba, Nobuaki Dobashi, Akihiro Tomita, Hironori Harada, Hiroshi Handa, Shigeo Horiike, Tomoya Maeda, Mitsuhiro Matsuda, Motoshi Ichikawa & Sumihisa Honda. (2022) Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. International Journal of Hematology 116:2, pages 228-238.
Crossref
Crossref
Michael Leisch, Michael Pfeilstöcker, Reinhard Stauder, Sonja Heibl, Heinz Sill, Michael Girschikofsky, Margarete Stampfl-Mattersberger, Christoph Tinchon, Bernd Hartmann, Andreas Petzer, Martin Schreder, David Kiesl, Sonia Vallet, Alexander Egle, Thomas Melchardt, Gudrun Piringer, Armin Zebisch, Sigrid Machherndl-Spandl, Dominik Wolf, Felix Keil, Manuel Drost, Richard Greil & Lisa Pleyer. (2022) Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group. Cancers 14:10, pages 2459.
Crossref
Crossref
Elizabeth A. Griffiths. (2021) Oral hypomethylating agents: beyond convenience in MDS. Hematology 2021:1, pages 439-447.
Crossref
Crossref
Ziqi Wan & Bing Han. (2021) High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies. Aging 13:8, pages 11120-11134.
Crossref
Crossref
Shyamala C. Navada. 2021. Medical Epigenetics. Medical Epigenetics
585
595
.
M. Tobiasson & A. O. Kittang. (2019) Treatment of myelodysplastic syndrome in the era of next‐generation sequencing. Journal of Internal Medicine 286:1, pages 41-62.
Crossref
Crossref
Amer M. Zeidan, Rory M. Shallis, Rong Wang, Amy Davidoff & Xiaomei Ma. (2019) Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews 34, pages 1-15.
Crossref
Crossref
David P. Steensma, Andrew M. Brunner, Amy E. DeZern, Guillermo Garcia‐Manero, Rami S. Komrokji, Olatoyosi S. Odenike, Gail J. Roboz, Michael R. Savona, Richard M. Stone & Mikkael A. Sekeres. (2018) Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer 124:24, pages 4601-4609.
Crossref
Crossref
Rory M. Shallis & Amer M. Zeidan. (2018) More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology 18:1.
Crossref
Crossref
Michael R. Savona, Kathryn Kolibaba, Paul Conkling, Edwin C. Kingsley, Carlos Becerra, John C. Morris, Robert M. Rifkin, Eric Laille, Amy Kellerman, Stacey M. Ukrainskyj, Qian Dong & Barry S. Skikne. (2018) Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. American Journal of Hematology 93:10, pages 1199-1206.
Crossref
Crossref
Amer M. Zeidan, Maximilian Stahl, Michelle DeVeaux, Smith Giri, Scott Huntington, Nikolai Podoltsev, Rong Wang, Xiaomei Ma, Amy J. Davidoff & Steven D. Gore. (2018) Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. Blood Cancer Journal 8:6.
Crossref
Crossref
Rami Komrokji, Arlene S. Swern, David Grinblatt, Roger M. Lyons, Magnus Tobiasson, Lewis R. Silverman, Hamid Sayar, Ravi Vij, Albert Fliss, Nora Tu & Mary M. Sugrue. (2018) Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. The Oncologist 23:2, pages 159-170.
Crossref
Crossref
Amer M. Zeidan, Maximilian Stahl, Mikkael A. Sekeres, David P. Steensma, Rami S. Komrokji & Steven D. Gore. (2017) A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer 123:19, pages 3662-3672.
Crossref
Crossref
Mikkael A. SekeresMegan OthusAlan F. ListOlatoyosi OdenikeRichard M. StoneSteven D. GoreMark R. LitzowRena BucksteinMin FangDiane RoulstonClara D. BloomfieldAnna MoseleyAziz NazhaYanming ZhangMario R. VelascoRakesh GaurEhab AtallahEyal C. AttarElina K. CookAlyssa H. CullMichael J. RauhFrederick R. AppelbaumHarry P. Erba. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. Journal of Clinical Oncology 35:24, pages 2745-2753.
Crossref
Crossref
Valeria Santini. (2017) First-line Therapeutic Strategies for Myelodysplastic Syndromes. Clinical Lymphoma Myeloma and Leukemia 17, pages S31-S36.
Crossref
Crossref
Vasiliki Pappa, Achilles Anagnostopoulos, Eleni Bouronikou, Evangelos Briasoulis, Ioannis Kotsianidis, Maria Pagoni, Panagiotis Zikos, Konstantinos Tsionos, Nora Viniou, John Meletis, Helen Papadaki, Anna Kioumi, Athanasios Galanopoulos, Elisavet-Christine Vervessou, Elias Poulakidas, Panagiotis Karmas, Kiki Karvounis & Argiris Symeonidis. (2016) A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece. International Journal of Hematology 105:2, pages 184-195.
Crossref
Crossref
Amer M. Zeidan, Amy J. Davidoff, Jessica B. Long, Xin Hu, Rong Wang, Xiaomei Ma, Cary P. Gross, Gregory A. Abel, Scott F. Huntington, Nikolai A. Podoltsev, Uno Hajime, Thomas Prebet & Steven D. Gore. (2016)
Comparative clinical effectiveness of azacitidine
versus
decitabine in older patients with myelodysplastic syndromes
. British Journal of Haematology 175:5, pages 829-840.
Crossref
Crossref
A M Zeidan, M A Sekeres, G Garcia-Manero, D P Steensma, K Zell, J Barnard, N A Ali, C Zimmerman, G Roboz, A DeZern, A Nazha, E Jabbour, H Kantarjian, S D Gore, J P Maciejewski, A List & R Komrokji. (2015) Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia 30:3, pages 649-657.
Crossref
Crossref
S. Bhalla & S.C. Navada. 2016. Medical Epigenetics. Medical Epigenetics
621
631
.